NEWPORT BEACH, CA--(NewMediaWire - Mar 22, 2017) - ADVANTIS
CORPORATION (OTC PINK: ADVT) is introducing a new line of premium
concentrate-infused products that it will make available through
its existing business partners, before kicking off a new marketing
campaign. Advantis CEO, Christopher Swartz will comment further on
this product line along with providing a future outlook and
shareholder update on Small Cap Voice next week.
"This is a luxury-inspired, premium quality, vacuum
concentrate-infused cannabis amalgamation that is more powerful
than anything we've seen in the marketplace," Advantis CEO,
Christopher Swartz, said. "Our current clients and partners, like
our friends at Speedweed, are excited about supplying this more
concentrated version of medicine to their member-patients. We are
in negotiations with some to expand our product exposure to
hundreds of new cooperatives around the state." Swartz hinted at
some of the features of the new product line. "Several different
exotic flavor profiles of some of the most potent medicine you may
ever have, including strawberry, coconut and others," Swartz
added.
Swartz says that the company has been in negotiations with
several companies that have shown great interest in the direction
Advantis is going in. "We are proactively responding to the growing
demand for innovative, premium quality products. Concentrates,
vapes, oils, rosin presses, premium pre-rolled, and of course
packaging; We are at the forefront of innovative solutions and
supply only the most sought after products." Advantis partners with
cultivators, dispensaries and other cooperative based organizations
to co-brand products and deliver developed shared and/or
proprietary products to its client base. "This new line of products
is just the tip of the iceberg," Swartz projected, "and with our
current business process we can hypothetically introduce almost any
premium in-demand product and have a ready market for
it."
Next week, Swartz will be interviewed by Small Cap Voice's,
Stuart Smith. Swartz says he is excited to answer shareholder
questions and provide some insight into the company business.
"Shareholders can fill out the questionnaire on our website, and I
will answer some of the more popular asked questions," Swartz said.
"I am so proud of the work we are doing here; I want to share with
our shareholders the story of how we got here and what the amazing
future holds for Advantis." Swartz says shareholders can ask
questions before the interview next week. He added that the company
will announce its sponsorship of a podcast in the near future. The
interview will be posted on the Advantis company website after it
concludes.
Links to Advantis websites can be found at advantiscorp.com, rosin6.com, elixicure.com, and amstercan.com
Follow us on Social Media Facebook Instagram Twitter
Forward Looking Statements: This news release contains
forward-looking statements made by ADVANTIS CORPORATION. All such
statements included in this press release, other than statements of
historical fact, are forward-looking statements. Although
management believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance
that such expectations will prove to have been correct. Actual
results may differ materially from those indicated by these
statements. The following risk factors, among others, could cause
actual results to differ materially from those described in any
forward- looking statements. These risks and uncertainties include,
but are not limited to, economic conditions, changes in the law or
regulations, demand for products of the Company, the effects of
competition and other factors that could cause actual results to
differ materially from those projected or represented in the
forward looking statements. Forward- looking statements are
typically identified by the words: believe, expect, anticipate,
intend, estimate, and similar expressions or which by their nature
refer to future events. The Company is not entitled to rely on the
safe harbor provisions of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934 because it
is not registered under eitherAct.